id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-346015-bzeqs5oh	Wang, Yeming	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	2020-04-29		.txt	text/plain	5233	246	46	Although several approved drugs and investigational agents have shown antiviral activity against SARS-CoV-2 in vitro, 6, 7 at present there are no antiviral therapies of proven effectiveness in treating severely ill patients with A multicentre, open-label, randomised controlled trial (RCT) of hydroxychloroquine involving 150 adults admitted to hospital for COVID-19 reported no significant effect of the drug on accelerating viral clearance. This was an investigator-initiated, individually randomised, placebo-controlled, double-blind trial to assess the effectiveness and safety of intravenous remdesivir in adults (aged ≥18 years) admitted to hospital with severe COVID-19. Our study is the first randomised, double-blind, placebocontrolled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19. Future studies of remdesivir, including earlier treatment in patients with COVID-19 and higher-dose regimens or in combination with other antivirals or SARS-CoV-2 neutralising antibodies in those with severe COVID-19 are needed to better understand its potential effectiveness.	./cache/cord-346015-bzeqs5oh.txt	./txt/cord-346015-bzeqs5oh.txt